The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRB..L Share News (RB.)

  • There is currently no data for RB.

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Former Indivior CEO pleads guilty in U.S. in opioid addiction treatment probe

Tue, 30th Jun 2020 21:48

(Adds comment from defense lawyer and Indivior)

By Nate Raymond

June 30 (Reuters) - Shaun Thaxter, the former chief
executive of drugmaker Indivior Plc, pleaded guilty on
Tuesday to a criminal charge arising out of a U.S. Justice
Department investigation into the marketing of its opioid
addiction treatment Suboxone.

Thaxter pleaded guilty in federal court in Abingdon,
Virginia to a misdemeanor count of introducing misbranded drugs
into interstate commerce. The plea came a day after Indivior
said he was stepping down as CEO.

Prosecutors said Thaxter failed to prevent employees from
sharing misleading safety information about the drug with
Massachusetts' Medicaid program as it considered expanding
coverage for it.

Wick Sollers, his attorney, said Thaxter was "unaware of the
alleged misstatements when they were made." Thaxter faces up to
one year in prison when he is sentenced on Sept. 29 and has
agreed to pay $600,000 in fines and forfeitures.

The plea came after Indivior in April 2019 was indicted and
charged with engaging in an illegal scheme to boost
prescriptions of Suboxone in one of the few corporate
prosecutions related to the U.S. opioid addiction
epidemic.

Prosecutors alleged Indivior deceived doctors and healthcare
benefit programs into believing the film version of Suboxone,
which has an opioid component, was safer and less susceptible to
abuse than similar drugs.

The indictment said Indivior also used an internet and
telephone program touted as a resource for opioid addicts to
connect them to doctors it knew were prescribing Suboxone and
other opioids at high rates and in suspect circumstances.

Prosecutors said the scheme began before British consumer
goods company Reckitt Benckiser spun off Indivior.
Reckitt Benckiser last year agreed to pay $1.4 billion to
resolved related claims.

Slough, England-based Indivior denies wrongdoing and is
scheduled to face trial in September. Indivior on Tuesday said
it is working to "resolve outstanding investigations and
litigations as expeditiously as possible."
(Reporting by Nate Raymond in Boston
Editing by Chris Reese and Marguerita Choy)

More News
27 Nov 2020 11:56

TOP NEWS: Reckitt Submits GBP1 Billion Claim Against Indivior

TOP NEWS: Reckitt Submits GBP1 Billion Claim Against Indivior

Read more
27 Nov 2020 11:44

Indivior tumbles as Reckitt Benckiser makes £1bn claim

(Sharecast News) - Indivior shares tumbled on Friday after the opioid addiction treatment maker said it had been made aware of a £1.07bn claim against it by consumer goods company Reckitt Benckiser.

Read more
25 Nov 2020 16:44

UK DIRECTOR DEALINGS SUMMARY: IG Design Chair Banks GBP1.2 Million

UK DIRECTOR DEALINGS SUMMARY: IG Design Chair Banks GBP1.2 Million

Read more
25 Nov 2020 16:23

Director dealings: Reckitt Benckiser CEO ups stake

(Sharecast News) - Reckitt Benckiser revealed on Wednesday that chief executive Laxman Narasimhan had acquired 7,930 ordinary shares in the FTSE 200-listed Dettol maker.

Read more
24 Nov 2020 06:44

DIRECTOR DEALINGS: Reckitt Benckiser Chair Buys GBP250,000 In Shares

DIRECTOR DEALINGS: Reckitt Benckiser Chair Buys GBP250,000 In Shares

Read more
19 Nov 2020 13:38

Thursday broker round-up

(Sharecast News) - easyJet: Liberum upgrades to buy with a target price of 1,300p.

Read more
19 Nov 2020 12:42

Jefferies downgrades Reckitt, says vaccine rollout alters landscape

(Sharecast News) - Jefferies downgraded its rating on shares of consumer goods giant and Dettol maker Reckitt Benckiser on Thursday to 'underperform' from 'hold' and slashed the price target to 5,845p from 7,100p.

Read more
19 Nov 2020 09:55

UK BROKER RATINGS SUMMARY: Liberum Upgrades easyJet, Davy Downgrades

UK BROKER RATINGS SUMMARY: Liberum Upgrades easyJet, Davy Downgrades

Read more
16 Nov 2020 11:56

LONDON MARKET MIDDAY: Momentum Continues On Vaccine Hopes, Upbeat Data

LONDON MARKET MIDDAY: Momentum Continues On Vaccine Hopes, Upbeat Data

Read more
13 Nov 2020 17:25

UPDATE 2-FTSE 100 dips but still posts best week since April on vaccine hopes

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* UK-EU to resume Brexit trade talks on Monday* Galliford surges on return to profitability forecast* Whitbread jumps on Barclays' upgrade to...

Read more
11 Nov 2020 09:45

UK BROKER RATINGS SUMMARY: Goldman Sachs And BofA Both Lift IAG To Buy

UK BROKER RATINGS SUMMARY: Goldman Sachs And BofA Both Lift IAG To Buy

Read more
6 Nov 2020 09:36

UK BROKER RATINGS SUMMARY: Panmure Says Buy AVEVA, Hold RSA

UK BROKER RATINGS SUMMARY: Panmure Says Buy AVEVA, Hold RSA

Read more
6 Nov 2020 08:22

LONDON BRIEFING: RSA Insurance Backs GBP7 Billion Buy And Divide Plan

LONDON BRIEFING: RSA Insurance Backs GBP7 Billion Buy And Divide Plan

Read more
23 Oct 2020 09:29

UK BROKER RATINGS SUMMARY: Reckitt Lifted; Liberum Resumes IAG At Hold

UK BROKER RATINGS SUMMARY: Reckitt Lifted; Liberum Resumes IAG At Hold

Read more
22 Oct 2020 13:59

Thursday broker round-up

(Sharecast News) - Abcam: Berenberg downgrades to hold with a target price of 1,180p.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.